Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Brain
Status:
Open
A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
NCT#04729959
BN010, dose level 3 is reopened to accrual, effective February 6, 2024, with the implementation of Amendment 3.
